Ladenburg Thalmann Downgrades SAB Biotherapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Jeffrey Cohen has downgraded SAB Biotherapeutics (NASDAQ:SABS) from Buy to Neutral.

October 05, 2023 | 2:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
SAB Biotherapeutics has been downgraded from Buy to Neutral by Ladenburg Thalmann, which could potentially impact the stock's performance.
Analyst ratings often influence the market's perception of a stock. A downgrade from Buy to Neutral indicates that the analyst sees less upside potential, which could lead to a decrease in demand for the stock and potentially lower its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100